β€’
Dec 30, 2022

Aramark Q1 2023 Earnings Report

Aramark's Q1 2023 performance reflected continued financial and operational momentum despite a challenging macro-environment.

Key Takeaways

Aramark reported a strong first quarter in fiscal year 2023, with revenue up 17% and organic revenue up 18%. The company's performance was driven by net new business, pricing, and base business growth across all reportable segments. Operating income increased by 42%, and adjusted operating income rose by 47%, driven by leveraging higher revenue, pricing, and cost management. EPS grew by 65% to $0.28, and adjusted EPS increased by 91% to $0.44.

Revenue increased by 17%, with organic revenue growth of 18%, driven by net new business, pricing, and base business growth across all reportable segments.

Operating Income increased by 42%, and Adjusted Operating Income (AOI) increased by 47%, driven by leveraging higher revenue levels, pricing, and operational cost management.

EPS increased by 65% to $0.28, and Adjusted EPS increased by 91% to $0.44.

Aramark announced the sale of a non-controlling interest in AIM Services for $535 million, with proceeds intended for accelerated debt repayment.

Total Revenue
$4.6B
Previous year: $3.95B
+16.5%
EPS
$0.44
Previous year: $0.22
+100.0%
Organic Revenue Change
18%
Previous year: 41%
-56.1%
Gross Profit
$439M
Previous year: $377M
+16.4%
Cash and Equivalents
$288M
Previous year: $415M
-30.6%
Total Assets
$15.3B
Previous year: $14.5B
+5.7%

Aramark

Aramark

Forward Guidance

Aramark maintained its outlook for organic revenue growth between +11% and +13% and Free Cash Flow in a range of $475 million to $525 million, before certain payments and costs. The company updated its Adjusted Operating Income (AOI) growth to +32% to +37%, reflecting the AIM Services Transaction, which is expected to be accretive to EPS. The leverage ratio is expected to be approximately 4.0x by the end of fiscal 2023.

Positive Outlook

  • Organic revenue growth between +11% and +13%
  • Free Cash Flow in a range of $475 million to $525 million, before the payment of deferred payroll taxes associated with the CARES Act as well as spin-off and restructuring related costs
  • Free Cash Flow in a range of $300 million to $350 million after these items
  • Adjusted Operating Income (AOI) growth of +32% to +37%
  • Transaction expected to be accretive to EPS